In brief
Bob Nelsen argues that biotech investing should be driven by scientific and clinical impact rather than by returns, and that ARCH's new $1.85 billion Fund 11 follows that rule. He says the money is a tool, not the goal. The priorities he names are mental health, manufacturing, delivery of cell and gene therapies, and rejuvenation, with incremental products avoided.
The tension is scale. Large funds usually lose their edge or start just "putting money to work," so Nelsen describes ARCH's workarounds. These include "X" innovation divisions inside portfolio companies, raising the smallest round that attracts the best investors, and building Resilience as shared manufacturing. He admits the hardest bottleneck is great company builders, not capital, and that policy and market cycles could still hurt.
Questions
What is ARCH Venture Partners' Fund 11 and how big is it?
Host Luke Timmerman calls it a $1.85 billion fund for new biotech startups, which Bob Nelsen describes as covering everything from $50,000 early checks to roughly $250 million for big projects.
Why does Bob Nelsen think a huge fund won't ruin ARCH's early-stage approach?
He says the risk is real, since big funds often lose their edge or fixate on 'putting money to work.' He argues ARCH has handled both small and large deals in Funds 8, 9 and 10 by keeping the scientific bar high and judging deals by impact, not money.
What is Resilience, the manufacturing company Nelsen talks about?
It is a company ARCH backed to make cells, viral vectors (virus-based delivery vehicles for gene therapy) and gene edits faster, cheaper and more consistently. Nelsen wants it to be the obvious outsourced choice, the way TSMC is for chips.
Why does Nelsen favor surrogate endpoints in Alzheimer's and Parkinson's trials?
A surrogate endpoint is a measurable marker, such as blood pressure, used in place of waiting years for a clinical outcome like a heart attack. Nelsen says we already approve hypertension drugs this way, so five-to-ten-year trials for brain disease are unnecessary, and drugs can be pulled later if they fail.
How does Nelsen expect drug-pricing politics under the Biden administration to affect biotech?
He expects some 'crazy' pricing proposals in Congress but thinks most Democrats understand the value of US biotech innovation. He warns that attacks on pharma tend to cut funding for biotech, even though pharma needs to buy or partner for innovation.
Facts
Stated by the speakers. Each quote matches the transcript, which shows what was said, not that it is true.
ARCH Venture Partners' Fund 11 is described by host Luke Timmerman as a $1.85 billion fund for investing in new biotech startups.
“Now for this conversation, I focus mainly on what Bob and the Arch investing team want to do with the latest fund, Fund 11. It's a $1.85 billion colossus to invest in new biotech startups.”
0:01:10 · Luke Timmerman · Fund 11
Bob Nelsen was an early investor in Illumina, Alnylam, Juno and Vir, according to Luke Timmerman.
“He was an early investor in gene sequencing technology with Illumina, RNA interference with alnylam, cell therapy with Juno, and infectious disease with Vir.”
0:00:33 · Luke Timmerman · Past investments
Matthew Herper wrote a profile of Bob Nelsen for Forbes in 2016.
“Matt Herper wrote a nice profile of Bob for Forbes in 2016.”
0:01:44 · Luke Timmerman · Media profile · 2016
Luke Timmerman began covering biotech at the Seattle Times, where he met Bob Nelsen early in Nelsen's time at ARCH.
“He was one of the first people I met when starting out covering biotech at the Seattle Times.”
0:00:33 · Luke Timmerman · Host background
ARCH's Fund 11 press release said it would still write investments ranging from $50,000 to $250 million.
“But you mentioned that you're still going to do these $50 ,000 checks all the way up to $250 million, whatever the thing requires.”
0:06:02 · Luke Timmerman · Check sizes
Luke Timmerman says the Fund 11 press release lists infectious disease, mental health, immunology, oncology, neurology, manufacturing, clinical trials, anti-aging, genomic and biological tools, and data sciences among its areas.
“Infectious disease, mental health, immunology, oncology, neurology, manufacturing, clinical trials, anti-aging, genomic, biological tools, data sciences.”
0:13:07 · Luke Timmerman · Investment areas
Bob Nelsen cites Prime as a company incubated within Beam as an example of ARCH's company-within-company model.
“Well, I think an example would be that Prime is kind of has incubated within Beam.”
0:10:41 · Bob Nelsen · Incubation model
Bob Nelsen contrasts Flagship Pioneering's incubation of companies within Flagship with ARCH's model of incubating companies within existing portfolio companies.
“While Flagship might incubate companies, a bunch of companies within Flagship, we have a model that's kind of incubating companies within companies.”
0:10:41 · Bob Nelsen · Incubation model
Bob Nelsen says the Japanese government appointed a minister of loneliness, citing it amid concern about suicides in Japan.
“I think the Japanese government just appointed a minister of loneliness.”
0:15:03 · Bob Nelsen · Mental health · 2021
Bob Nelsen says people with two copies of the APOE4 gene variant, which he calls APOE44, are probably going to get Alzheimer's disease.
“We know if you have an APOE44, you're probably going to get it.”
0:18:20 · Bob Nelsen · Alzheimer's genetics
Bob Nelsen suggests cell therapy companies could run their own treatment centers next to hospitals, owned by the company that manufactures the cells.
“maybe you create a cell therapy center that sits next to a big hospital but it's it's you know essentially owned by the company that's manufacturing the cells.”
0:21:27 · Bob Nelsen · Healthcare delivery
Bob Nelsen argues the world's pandemic response was inadequate, noting it took about a year and roughly half a million deaths in the US to reach vaccines.
“It only took a year and a half a million dead people, right?”
0:23:30 · Bob Nelsen · COVID-19 response · 2021
Bob Nelsen says Resilience should become the obvious outsourcing choice for biologic manufacturing, using TSMC as a model.
“obvious that you should work with us versus doing it yourself and you know tsmc is a good model for that”
0:26:18 · Bob Nelsen · Resilience strategy
Bob Nelsen says the semiconductor industry's heavy investment in better, faster, cheaper manufacturing drove the entire computer industry, and biotech can learn from that.
“they actually invest a lot of money um and technology figuring out how to make stuff uh way better faster cheaper and that's what drove the entire computer industry”
0:26:18 · Bob Nelsen · Manufacturing
Bob Nelsen questions whether antibodies must be made in large steel tanks and suggests making them inside the body instead.
“Do we have to make antibodies in big giant steel tanks? Maybe we should make them in the body.”
0:27:13 · Bob Nelsen · Biomanufacturing
Bob Nelsen says an immortalized B cell could, in principle, supply all the vaccines a person would ever need.
“if I can make an immortalized B cell I could give you all of the vaccines you would ever need in your lifetime”
0:28:35 · Bob Nelsen · Cell therapy
Bob Nelsen says the biggest threat to the biotech industry was the drug-pricing agenda of Elizabeth Warren and Bernie Sanders, which he says did not come to pass.
“the big threat to the industry was the Elizabeth Warren crazy, Bernie Sanders crazy, you know, see crazy that, you know, don't really understand innovation is actually the solution to public health, not the problem.”
0:31:04 · Bob Nelsen · Drug pricing · 2021
Bob Nelsen argues that requiring five-to-ten-year trials instead of using surrogate endpoints for Alzheimer's and Parkinson's drugs is unreasonable.
“we can't, you know, develop intermediate markers for Alzheimer's or Parkinson's or, you know, other chronic and debilitating disease and that we have to have, you know, five or 10 year long clinical development cycles is just crazy.”
0:36:47 · Bob Nelsen · Surrogate endpoints
Bob Nelsen says ARCH typically spends about a month trying to reduce the size of a company's financing round to raise the minimum needed from the best investors.
“And almost certainly we spent like a month trying to cut back the size of the round.”
0:39:48 · Bob Nelsen · Funding rounds
Bob Nelsen says Sana Biotechnology's successful IPO as a preclinical company reflected investors who evaluated the data and long-term potential rather than short-term news flow.
“well, how is Sana so successful in their IPO being a preclinical company, right? It's because people actually looked at the data and thought about where they could be in five or ten years.”
0:41:50 · Bob Nelsen · Sana IPO · 2021
Bob Nelsen says ARCH has banned the phrase 'news flow' as part of its long-term, science-driven investing culture.
“Yeah, we banned the word news flow from Arch.”
0:42:25 · Bob Nelsen · ARCH culture
Bob Nelsen predicted the United States would reach herd immunity against COVID-19 before other major countries because of its strong vaccines and low mask compliance.
“the fact that we have the best vaccine and the stupidest group of people that don't wear masks will conspire together to have the U.S. reach herd immunity probably before any other major country.”
0:44:36 · Bob Nelsen · Herd immunity · 2021